3 503

Cited 40 times in

Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model

DC Field Value Language
dc.contributor.author방동식-
dc.date.accessioned2015-05-19T16:59:22Z-
dc.date.available2015-05-19T16:59:22Z-
dc.date.issued2008-
dc.identifier.issn0923-1811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/107318-
dc.description.abstractBACKGROUND: Anti-TNFalpha antibodies have been used for treating inflammation in patients. But, more effective and safer drugs need to be developed for improved future therapeutic use. OBJECTIVES: To inhibit the expression of TNFalpha, we used small interfering RNAs (siRNAs) to reduce over expression of TNFalpha in vitro in cell cultures and in an in vivo Behcet's disease-like (BD) mouse model for amelioration of chronic inflammation. METHODS: TNFalpha siRNA was injected intraperitoneally twice with a 1-week interval. To compare the efficacy of TNFalpha siRNA versus an anti-TNFalpha antibody, Infliximab and Etanercept were administered to symptomatic mice with inflamed tissue. RESULTS: Intraperitoneal delivery of TNFalpha siRNA effectively decreased BD symptoms in 18 of 32 cases (56.3%). Scrambled siRNA treatment decreased BD symptoms in 2 of 19 cases (10.5%). Infliximab was effective in 11 of 27 cases (40.7%) and Etanercept was also effective in 9 of 25 cases (36.0%) at the end of the second week after treatment. TNFalpha siRNA reduced serum levels of TNFalpha (1.57 +/- 0.43pg/ml), compared to levels in mice not injected (84.02 +/- 24.59pg/ml) (p<0.01) or scramble injected (118.89 +/- 20.08pg/ml) (p<0.01). After single injection of TNFalpha siRNA, improvement of BD symptoms showed at 9 +/- 7th day on an average, contrary, in Infliximab injected group, improvement was apparent at 15 +/- 4th day after injection (p<0.05). CONCLUSION: We show that siRNAs can be employed to inhibit cytokine gene expression in an in vivo disease mouse model. This inhibition may, therefore, be attributed to the improvement of inflammatory symptoms.-
dc.description.statementOfResponsibilityopen-
dc.format.extent87~97-
dc.relation.isPartOfJOURNAL OF DERMATOLOGICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAnti-Inflammatory Agents/pharmacology-
dc.subject.MESHAnti-Inflammatory Agents/therapeutic use-
dc.subject.MESHAntibodies, Monoclonal/pharmacology-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use-
dc.subject.MESHBehcet Syndrome/drug therapy*-
dc.subject.MESHBehcet Syndrome/metabolism-
dc.subject.MESHBehcet Syndrome/virology*-
dc.subject.MESHCells, Cultured-
dc.subject.MESHCytokines/metabolism-
dc.subject.MESHDisease Models, Animal-
dc.subject.MESHEtanercept-
dc.subject.MESHImmunoglobulin G/pharmacology-
dc.subject.MESHImmunoglobulin G/therapeutic use-
dc.subject.MESHInfliximab-
dc.subject.MESHLipopolysaccharides/metabolism-
dc.subject.MESHMacrophages/drug effects-
dc.subject.MESHMacrophages/metabolism-
dc.subject.MESHMale-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred ICR-
dc.subject.MESHRNA, Small Interfering/pharmacology-
dc.subject.MESHRNA, Small Interfering/therapeutic use*-
dc.subject.MESHReceptors, Tumor Necrosis Factor/therapeutic use-
dc.subject.MESHSimplexvirus/pathogenicity*-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Necrosis Factor-alpha/antagonists & inhibitors-
dc.subject.MESHTumor Necrosis Factor-alpha/genetics*-
dc.subject.MESHTumor Necrosis Factor-alpha/metabolism-
dc.titleTumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학)-
dc.contributor.googleauthorBunsoon Choi-
dc.contributor.googleauthorYunchung Hwang-
dc.contributor.googleauthorHyuk Jae Kwon-
dc.contributor.googleauthorEun-So Lee-
dc.contributor.googleauthorKyung Sook Park-
dc.contributor.googleauthorDongsik Bang-
dc.contributor.googleauthorSungnack Lee-
dc.contributor.googleauthorSeonghyang Sohn-
dc.identifier.doi10.1016/j.jdermsci.2008.05.001-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01784-
dc.relation.journalcodeJ01370-
dc.identifier.eissn1873-569X-
dc.identifier.pmid18585901-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0923181108001540-
dc.subject.keywordTNF alpha-
dc.subject.keywordSiRNA-
dc.subject.keywordHerpes simplex virus-
dc.subject.keywordMouse model-
dc.subject.keywordBehcet's disease-
dc.subject.keywordIn vivo-
dc.contributor.alternativeNameBang, Dong Sik-
dc.contributor.affiliatedAuthorBang, Dong Sik-
dc.rights.accessRightsnot free-
dc.citation.volume52-
dc.citation.number2-
dc.citation.startPage87-
dc.citation.endPage97-
dc.identifier.bibliographicCitationJOURNAL OF DERMATOLOGICAL SCIENCE, Vol.52(2) : 87-97, 2008-
dc.identifier.rimsid48287-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.